MDS: Disease Burden, Molecular Targets, and Why Single-Agent Therapy Falls Short
Myelodysplastic syndromes (MDS) affect an estimated 15,000–20,000 new patients in the United States each year, with incidence rising steeply with age to approximately 22–45 per 100,000 in individuals over 70. The disease is defined by clonal hematopoietic stem cell dysfunction causing ineffective hematopoiesis across one or more myeloid lineages, peripheral cytopenias — including anemia, thrombocytopenia, and neutropenia — and a well-documented risk of progression to acute myeloid leukemia (AML). Clonal cytogenetic abnormalities are detectable in approximately 50% of MDS cases, underscoring the genetic heterogeneity that has historically complicated treatment development.
The molecular landscape of MDS is defined by mutations across several key pathways. Somatic mutations in SF3B1, TET2, DNMT3A, ASXL1, CUX1, IDH2, TP53, STAG2, and NRAS are cited across the patent dataset as disease-defining or treatment-stratifying markers. The Broad Institute has filed patents identifying mutational signatures across these genes — collectively referred to as “Table 3a genes” — as predictive biomarkers for hypomethylating agent (HMA) response. This mutational complexity is precisely why azacitidine and decitabine monotherapy — while foundational — produce complete remissions in only a minority of patients, with clinical benefits that are frequently transient according to Novartis AG’s own patent rationale for combination strategies.
Azacitidine and decitabine are nucleoside analogues that inhibit DNA methyltransferase (DNMT), reversing aberrant hypermethylation of tumour suppressor genes in hematopoietic progenitor cells. They are the most widely referenced drug class across the MDS patent dataset and serve as backbone agents in nearly every combination strategy described, from immune checkpoint co-blockade to HDAC and CDK9 inhibition.
Key molecular targets identified across the retrieved patent dataset span at least seven distinct mechanistic classes: telomerase/hTERT, activin receptor type II (ActRII)/TGF-β superfamily, DNA methylation/DNMT, CD47/SIRPα phagocytic checkpoint, TIM-3/TGF-β immune checkpoint, JAK1, and IDH2. Each target has attracted dedicated patent prosecution from named assignees, with PatSnap’s life sciences intelligence platform enabling systematic mapping of these overlapping IP positions. According to WHO classification frameworks, MDS subtypes differ substantially in prognosis and therapeutic relevance, reinforcing the need for biomarker-driven patient selection embedded in treatment strategies.
Myelodysplastic syndrome (MDS) has an estimated U.S. incidence of 15,000–20,000 new cases annually, rising to approximately 22–45 per 100,000 in individuals over 70 years old, with clonal cytogenetic abnormalities detectable in approximately 50% of cases.
Imetelstat and Telomerase Inhibition: Precision Strategy in Low-Risk MDS
Imetelstat — a lipid-conjugated oligonucleotide telomerase inhibitor developed by Geron Corporation and co-prosecuted with Janssen Biotech — is the most specifically characterised single agent for MDS in the retrieved patent dataset. Its mechanism targets hTERT (telomerase reverse transcriptase), disrupting the self-renewal capacity of neoplastic progenitor cells responsible for clonal MDS propagation. The eligible patient population described in concordant Geron and Janssen filings is tightly defined: HMA-naive patients classified as low or intermediate-1 IPSS risk with relapsed or refractory ESA (erythropoiesis-stimulating agent) disease, or transfusion-dependent non-del(5q) patients requiring four or more units of red blood cell transfusion in the eight weeks prior to treatment.
“A 50% or greater reduction in hTERT expression following imetelstat treatment is described in Geron Corporation patents as predictive of clinical benefit — embedding companion diagnostics directly into the IP strategy.”
The precision biomarker strategy embedded in Geron’s patent claims goes beyond IPSS classification. Patents specify that monitoring variant allele frequency (VAF) reductions of 25% or greater in genes including SF3B1, TET2, DNMT3A, ASXL1, and CUX1 identifies subjects with increased likelihood of benefit. A 2025 Geron filing in China (through U.S. Geron Biopharmaceuticals, Inc.) describes methods to treat MDS and monitor treatment via hTERT expression tracking, signalling sustained prosecution through the most recent filing year in this dataset. The specificity of these eligibility criteria — including IPSS scoring, transfusion thresholds, ESA history, HMA naivety, and VAF monitoring — is consistent with post-Phase II clinical translation.
A University of California filing (2022, WO) extends the imetelstat story beyond MDS monotherapy, describing combinations with dasatinib, ruxolitinib, fedratinib, or 8-aza-adenosine for AML/MPN stem cell propagation inhibition. While this combination space has not yet been formally consolidated with the Geron/Janssen franchise in a single retrieved filing, it signals that telomerase inhibition is being explored as a platform rather than a single-indication asset. According to NIH clinical trial registries, telomerase inhibition in haematological malignancies has been an active area of investigation for over a decade, with imetelstat’s MDS-specific development representing the most advanced programme in this class.
Geron Corporation patents specify that imetelstat is indicated for HMA-naive MDS patients classified as low or intermediate-1 IPSS risk who are relapsed or refractory to ESA therapy, or transfusion-dependent non-del(5q) patients requiring four or more units of red blood cell transfusion in the eight weeks prior to treatment, with companion biomarker monitoring of hTERT expression and VAF reductions in SF3B1, TET2, DNMT3A, ASXL1, and CUX1.
Map the full imetelstat patent portfolio and identify white-space opportunities with PatSnap Eureka.
Explore MDS Patent Data in PatSnap Eureka →ActRII Ligand Traps: Luspatercept and the Expanding Erythropoiesis Correction Space
Luspatercept — an ActRIIB-Fc fusion protein that traps TGF-β superfamily ligands to restore late-stage erythroid differentiation — represents one approved approach to correcting MDS-associated anemia, but the patent dataset reveals that the ActRII signalling space extends considerably beyond a single approved agent. Keros Therapeutics has filed patents covering ActRIIA variant fusion proteins and chimeras that are structurally distinct from the ActRIIB-Fc architecture of luspatercept, targeting TGF-β superfamily ligands including activin, GDF-11, and GDF-8 to address ineffective erythropoiesis in MDS bone marrow niches.
The Keros filings specifically highlight patients with erythropoietin (EPO) levels greater than 100 mIU/mL as a patient-selection biomarker for this class — a threshold that identifies patients unlikely to respond to exogenous ESA supplementation and therefore candidates for upstream pathway correction. Critically, Keros patents describe ActRIIA variants addressing not only anemia but also thrombocytopenia and neutropenia, suggesting that the ligand trap approach may offer broader cytopenia correction than the erythropoiesis-focused framing of luspatercept’s approved indication. The IP activity in this space — with WO and IL filings from 2021–2022 — is entirely patent-driven in this dataset, indicating active prosecution around differentiated structural variants that may represent distinct IP positions with different ligand affinity profiles compared to the approved agent.
Keros Therapeutics patents cover ActRIIA variant chimeras structurally distinct from luspatercept’s ActRIIB-Fc architecture. This differentiation may represent a separate IP position with different ligand affinity profiles, potentially enabling coverage of thrombocytopenia and neutropenia — cytopenias beyond the erythropoiesis-focused scope of the approved luspatercept indication.
The mechanistic rationale for ActRII ligand traps in MDS is the excessive TGF-β superfamily signalling in the MDS bone marrow niche that drives aberrant late-stage erythroid differentiation. By trapping ligands including activin, GDF-11, and GDF-8, these fusion proteins relieve the suppression of erythroid progenitor maturation. As noted by EMA and FDA regulatory frameworks, the clinical development of this class has been informed by a growing understanding of the TGF-β pathway’s role in MDS pathophysiology, reinforcing the scientific rationale for continued IP prosecution in structurally differentiated variants.
Keros Therapeutics patents describe ActRIIA variant fusion proteins — structurally distinct from luspatercept’s ActRIIB-Fc architecture — that target TGF-β superfamily ligands (activin, GDF-11, GDF-8) to address anemia, thrombocytopenia, and neutropenia in MDS patients with erythropoietin levels greater than 100 mIU/mL.
HMA Combination Approaches: Immune Checkpoints, HDAC, CDK9, and Oral Formulations
Hypomethylating agents function as backbone agents across nearly every combination approach in the retrieved MDS patent dataset — paired with anti-CD47 antibodies, TIM-3 inhibitors, HDAC inhibitors, CDK9 inhibitors, and cytidine deaminase inhibitors. This combinatorial density reflects both the established clinical activity of HMAs and the well-recognised limitation that azacitidine monotherapy achieves complete remission in only a minority of patients, with benefits that are frequently transient. The primary competitive differentiation among HMA combinations lies in the co-agent mechanism and patient selection criteria.
Immune Checkpoint Combinations: Anti-CD47 and TIM-3
Forty Seven, Inc. (subsequently acquired by Gilead Sciences) has filed patents across EP, SG, AU, and CN jurisdictions covering magrolimab (anti-CD47) combined with azacitidine at 75 mg/m² on days 1–7 of 28-day cycles, with a specific priming and dose-escalation schedule (1–10 mg/kg priming; ≥15 mg/kg week 2; ≥30 mg/kg weeks 3–4). The anti-CD47 rationale is particularly compelling in TP53-mutant MDS, where the phagocytic checkpoint is described as a specific therapeutic vulnerability. Novartis AG filings describe a more complex multi-target approach: the TIM-3 antibody MBG453 combined with decitabine and/or the TGF-β inhibitor NIS793 and/or the anti-PD-1 antibody spartalizumab. Novartis explicitly acknowledges in its patent rationale that azacitidine monotherapy achieves only transient and incomplete remissions, motivating the multi-target immune co-blockade strategy.
HDAC and CDK9 Inhibition: Synergy via the NOXA/MCL-1 Axis
MEI Pharma patents describe pracinostat (a pan-HDAC inhibitor) combined with an HMA specifically for high and very high risk MDS, with 28-day cycle dosing schedules consistent with clinical trial design. The proposed synergistic mechanism involves HMA-induced NOXA re-expression combined with HDAC inhibitor-mediated MCL-1 suppression, creating a dual pro-apoptotic signal in MDS blasts. Sumitomo Pharma Oncology filings extend this mechanistic framework to CDK9 inhibition: alvocidib combined with azacitidine or decitabine is proposed to suppress MCL-1 through RNA Pol II inhibition while HMAs induce NOXA re-expression — a complementary action on the same apoptotic axis. Active IP prosecution through 2024 (US filing) indicates sustained commercial interest in this combination.
Oral HMA Formulations: Cedazuridine/Decitabine
The cedazuridine/decitabine oral combination — in which the cytidine deaminase inhibitor cedazuridine prevents first-pass degradation of decitabine — is described in patent filings as extending overall median survival to approximately 130–400% relative to HMA alone in lower-risk MDS and CMML, including TP53-mutant subjects. This survival claim appears in a 2023 patent filing by Harold Keer (WO), with Otsuka Pharmaceutical’s 2024 Brazil filing indicating recent international expansion of the combination’s IP prosecution. The specific dosing and the TP53-mutant patient subgroup coverage distinguish this combination from standard intravenous HMA regimens.
Analyse the full HMA combination patent landscape across assignees and jurisdictions with PatSnap Eureka.
Search MDS Combination Patents in PatSnap Eureka →A 2023 patent filing by Harold Keer (WO) describes the oral cedazuridine/decitabine combination as extending overall median survival to approximately 130–400% relative to HMA alone in lower-risk MDS and CMML, including TP53-mutant subjects. Otsuka Pharmaceutical’s 2024 Brazil filing confirms ongoing international IP prosecution of this combination.
Assignee Landscape and Strategic IP Implications for MDS Drug Development
The MDS patent landscape in this dataset is dominated by commercial pharmaceutical assignees, with academic and translational institutions representing a minority of sources. Understanding the assignee concentration and prosecution strategies is essential for drug developers, IP strategists, and investors evaluating competitive positioning in this space — a task for which PatSnap’s IP intelligence tools provide systematic landscape mapping across jurisdictions and filing dates.
Incyte Corporation: Broadest Jurisdictional Footprint
Incyte Corporation is the largest volume single assignee in this dataset overall, with JAK1 inhibitor patents filed across EP, ES, AU, IL (multiple), NZ, CA, MY, BR, and US jurisdictions — all deriving from a single priority application (US Provisional 61/946,124, filed February 28, 2014). This breadth signals an aggressive international prosecution strategy for JAK1-selective pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine chemotypes targeting JAK/STAT signalling in MDS cytokine dysregulation. The sustained prosecution from a 2014 priority date through 2023 CA filing indicates long-term commercial commitment to this target, though no outcomes data appear in the retrieved results.
Geron Corporation: Concentrated Imetelstat IP with Companion Diagnostic Integration
Geron Corporation is the most active single assignee for imetelstat-specific MDS IP, with filings across SG, NZ, CN, and WO jurisdictions spanning 2018–2025. The 2025 CN filing (through U.S. Geron Biopharmaceuticals, Inc.) represents the most recent activity in the dataset, indicating sustained prosecution. Critically, the companion biomarker strategy — VAF monitoring of SF3B1, TET2, DNMT3A, ASXL1, CUX1, and hTERT expression monitoring — is embedded directly in patent claims rather than described only in clinical protocols. This creates potential barriers to competitive entry and licensing leverage for any organisation seeking to commercialise telomerase inhibition in MDS without engaging with the Geron/Janssen portfolio.
Novartis AG: Immune Checkpoint Combination Dominance
Novartis AG dominates the immune checkpoint + HMA combination space in this dataset, with active and pending filings covering TIM-3, TGF-β, PD-1, IL-1β, and MDM2 inhibitor pathways across IL, AU, and CA jurisdictions. The multi-target immune co-blockade approach (MBG453 + NIS793 ± decitabine ± spartalizumab) represents one of the most complex combination strategies in the dataset. Competitors entering MDS immunotherapy combinations will face significant IP landscape challenges across these checkpoint targets. According to WIPO patent data, the intersection of immune checkpoint inhibition and haematological malignancies has been one of the fastest-growing areas of pharmaceutical IP prosecution globally over the past five years.
“Patient stratification biomarkers — including IPSS scoring, mutational profiles (TP53, IDH2, SF3B1, DNMT3A), transfusion dependence thresholds, and EPO levels — are increasingly embedded in MDS treatment patents as IP strategy tools, not merely clinical necessities.”
Emerging Assignees: Keros Therapeutics, Sumitomo, and Minovia
Beyond the dominant assignees, several emerging organisations signal active innovation in differentiated modalities. Keros Therapeutics (ActRIIA ligand traps), Sumitomo Pharma Oncology (CDK9 inhibition), and Minovia Therapeutics (mitochondria-enriched stem/progenitor cell therapy targeting ineffective hematopoiesis) each represent distinct mechanistic bets on MDS pathophysiology. Minovia’s approach — augmenting hematopoietic stem/progenitor cells with functional mitochondria — is the most structurally novel in the dataset, with a 2023 WO filing indicating early-stage but active prosecution. Cell-based approaches from Katholieke Universiteit Leuven (2016 EP) represent earlier-stage translational research in the dataset.
Patient stratification biomarkers — including IPSS scoring, mutational profiles (TP53, IDH2, SF3B1, DNMT3A), transfusion dependence thresholds, and EPO levels — are increasingly embedded in MDS treatment patents across the dataset. Organisations without companion diagnostic co-development capabilities may face commercialisation barriers even for differentiated therapeutic agents, as eligibility criteria embedded in method-of-treatment claims can restrict competitive use of a drug in the defined patient population.